Rocket Pharmaceuticals, Inc., a prominent player in the biotechnology sector, has recently disclosed several changes in beneficial ownership through Form 4 filings. The company, headquartered in New York, United States, specializes in developing gene therapies aimed at addressing rare and catastrophic pediatric diseases. This announcement was made on May 13, 2026, and highlights transactions involving key executive officers.
The transactions involved the sale of restricted stock units (RSUs) by General Counsel Wilson Martin, Chief Executive Officer Shah Gaurav, and Vice-President of Finance John Militello. These RSUs were converted into common shares and sold to fulfill tax withholding obligations associated with the RSU vesting schedule. Despite these sales, the officers continue to hold significant direct stakes in Rocket Pharmaceuticals’ common stock. Additionally, indirect holdings are reported by Gaurav Shah’s spouse and trust.
The company’s financial metrics provide further context to these developments. As of May 14, 2026, Rocket Pharmaceuticals’ close price stood at $3.25, with a 52-week high of $6.885 recorded on May 19, 2025, and a 52-week low of $2.19 on May 26, 2025. The market capitalization of the company is valued at approximately $354.88 million. The price-to-earnings ratio is currently at -1.74, reflecting the company’s financial performance and market valuation.
These ownership changes are indicative of routine corporate activities rather than any extraordinary market movements. The continued participation of management in the company’s equity underscores their commitment to Rocket Pharmaceuticals’ long-term vision and strategic goals. The company remains actively engaged in its core mission of advancing gene therapies for critical pediatric conditions, maintaining its position within the health care and biotechnology sectors.
